Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending April 8, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance disclosures regarding share ownership.
Material Changes
The primary material change reported is a transfer of shares within the GlaxoSmithKline Employee Trust ("GSK Trust"). On April 6, 2004, Abacus (GSK) Trustees Limited transferred 5,570 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991.
Management Commentary and Risks
The filing notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—hold an interest in the shares held by the trust in the same capacity as other employees. No specific risks, contingencies, or unusual items were disclosed in this text.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the April 6, 2004 transfer.
- Confirm the specific shareholding details for directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting conditions for the 5,570 transferred shares.